FILE:JPM/JPM-8K-20080911172250.txt.gz
EVENTS:	Financial Statements and Exhibits
TEXT:
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
  
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
  
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
  
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item  9.01.         Financial Statements and Exhibits
 
(d)       Exhibits
 
The following Exhibits are incorporated by reference into the Registration Statement on Form S-3ASR (333-130051) of JPMorgan Chase & Co. (the Registrant) as exhibits thereto and are filed as part of this Current Report.
 
 
2
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
Dated: September 11, 2008
 
3
 
 
 
 
 
 
 4

 
 
Exhibit 8.1
 
 
JPMorgan Chase & Co.
270 Park Avenue
New York, New York 10017
 
Ladies and Gentlemen:
We have acted as special tax counsel to JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware (the Company), in connection with the preparation and filing of pricing supplement no. 1542 dated September 8, 2008 relating to $2,000,000 Principal Protected Notes Linked to the Dow Jones  AIG Commodity Index due September 13, 2011 (the Pricing Supplement) to product supplement no. 32-XI dated August 1, 2008 relating to Principal Protected Notes Linked to a Weighted Basket Consisting of the AMEX Hong Kong 30 Index, the Dow Jones EURO STOXX 50Index, the Dow Jones  AIG Commodity Index, the S&P GSCIExcess Return Index, the S&P GSCI Agriculture Index Excess Return, the S&P GSCIEnergy Index Excess Return, the S&P GSCI Industrial Metals Index Excess Return, the S&P GSCILivestock Index Excess Return, the S&P GSCIPrecious Metals Index Excess Return, the FTSE100 Index, the FTSE/Xinhua China 25 Index, the Korea Stock Price Index 200, the MSCI EAFE Index, the iShares MSCI Emerging Markets Index Fund, the MSCI Taiwan Index, the MSCI Singapore Index, the Nikkei 225 Index, the Russell 2000Index, the Russell 3000Index and the S&P 500 Index, or Linked to Any One of the Foregoing (the Product Supplement) to a prospectus supplement dated October 12, 2006 (the Prospectus Supplement) for the Companys Global Medium-Term Notes, Series E, Global Warrants, Series E and Global Units, Series E, relating to a prospectus dated December 1, 2005 (the Prospectus) contained in the Companys Registration Statement on Form S-3ASR (Registration Statement No. 333-130051) (the Registration Statement).  This opinion is being furnished in accordance with the requirements of Section 601(b)(8) of Regulation S-K of the Securities Act of 1933, as amended (the Act).
SM
SM
TM
TM
TM
TM
TM
TM
TM
In our opinion, the discussions under the heading United States Federal Taxation in the Prospectus Supplement, under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement, subject to the conditions and limitations described therein, set forth the material U.S. federal income tax considerations applicable generally to holders of the securities offered pursuant to the Pricing Supplement as a result of the ownership and disposition of such securities.
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to us under the heading Certain U.S. Federal Income Tax Consequences in the Product Supplement and under the heading Selected Purchase Considerations  Taxed as Contingent Payment Debt Instruments in the Pricing Supplement.  By such consent we do not concede that we are an expert for the purposes of the Act.


